Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1,094.06
- Piotroski Score 6.00
- Grade Neutral
- Symbol (OGN)
- Company Organon & Co.
- Price $16.13
- Changes Percentage (2.09%)
- Change $0.33
- Day Low $15.95
- Day High $16.35
- Year High $23.10
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
- Last Earnings 10/31/2024
- Ex-Dividend for 5/16 Dividend 11/12/2024
- Dividend Payable 12/12/2024
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $24.00
- High Stock Price Target $24.00
- Low Stock Price Target $24.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $4.08
- Trailing P/E Ratio 5.09
- Forward P/E Ratio 5.09
- P/E Growth 5.09
- Net Income $1.02 B
Income Statement
Quarterly
Annual
Latest News of OGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
PrognomiQ secures funding to advance lung cancer detection test
PrognomiQ has raised $34m in Series D financing to develop an early lung cancer detection test. The company integrates Seer's proteomic platform to identify biomarkers for diagnostic and therapeutic d...
By Yahoo! Finance | 1 day ago -
Lipscomb takes on No. 16 Arkansas following Ognacevic's 30-point game
Lipscomb faces No. 16 Arkansas next, following Jacob Ognacevic's 30-point performance in their recent win....
By AP NEWS | 2 days ago -
Recognition at last for Tom Bacon, the scientist you've never heard of who helped put men on the moon
Francis Thomas Bacon, a Cambridge-based engineer, developed the hydrogen-oxygen fuel cell used in Apollo 11. His pioneering work in renewable energy is being honored with a blue plaque at his former h...
By The Guardian | 5 days ago
